CA1327168C - Anticorps monoclonaux anti-trichomonas vaginalis - Google Patents
Anticorps monoclonaux anti-trichomonas vaginalisInfo
- Publication number
- CA1327168C CA1327168C CA000546325A CA546325A CA1327168C CA 1327168 C CA1327168 C CA 1327168C CA 000546325 A CA000546325 A CA 000546325A CA 546325 A CA546325 A CA 546325A CA 1327168 C CA1327168 C CA 1327168C
- Authority
- CA
- Canada
- Prior art keywords
- monoclonal antibody
- trichomonas vaginalis
- complement
- antibody according
- trichomonas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003716 antitrichomonal agent Substances 0.000 title claims description 21
- 230000000295 complement effect Effects 0.000 claims abstract description 69
- 241000224527 Trichomonas vaginalis Species 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 40
- 208000005448 Trichomonas Infections Diseases 0.000 claims abstract description 24
- 206010044620 Trichomoniasis Diseases 0.000 claims abstract description 24
- 238000003745 diagnosis Methods 0.000 claims abstract description 11
- 230000002934 lysing effect Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 29
- 210000002966 serum Anatomy 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 25
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 20
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 20
- 230000009089 cytolysis Effects 0.000 claims description 19
- 230000004927 fusion Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 210000004989 spleen cell Anatomy 0.000 claims description 16
- 210000003567 ascitic fluid Anatomy 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 241000700199 Cavia porcellus Species 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 230000001472 cytotoxic effect Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940059082 douche Drugs 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000003 vaginal tablet Substances 0.000 claims description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 6
- 238000011200 topical administration Methods 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 229940044977 vaginal tablet Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 241000224526 Trichomonas Species 0.000 description 37
- 230000027455 binding Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 230000001461 cytolytic effect Effects 0.000 description 9
- 230000002101 lytic effect Effects 0.000 description 9
- 244000045947 parasite Species 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 108010028771 Complement C6 Proteins 0.000 description 1
- 101100353161 Drosophila melanogaster prel gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000557621 Trichomonas gallinae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical compound CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002865 vaccinogenic effect Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL79950A IL79950A0 (en) | 1986-09-05 | 1986-09-05 | Anti-trichomonas vaginalis mono-trichomonas clonal antibodies inducing complement-dependent cytotoxicity,their use in immunotherapy and immunodiagnosis |
| IL79950 | 1986-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1327168C true CA1327168C (fr) | 1994-02-22 |
Family
ID=11057112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000546325A Expired - Fee Related CA1327168C (fr) | 1986-09-05 | 1987-09-08 | Anticorps monoclonaux anti-trichomonas vaginalis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5004694A (fr) |
| EP (1) | EP0259807B1 (fr) |
| JP (1) | JPS63211298A (fr) |
| AU (1) | AU7779087A (fr) |
| CA (1) | CA1327168C (fr) |
| DE (1) | DE3787239T2 (fr) |
| ES (1) | ES2059336T3 (fr) |
| IL (1) | IL79950A0 (fr) |
| ZA (1) | ZA876627B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5876985A (en) * | 1991-04-25 | 1999-03-02 | Board Of Regents, The University Of Texas System | Methods and compositions for the preparation of recombinant Trichomonas vaginalis proteins and peptides |
| US7291477B2 (en) * | 2001-07-03 | 2007-11-06 | Xenotope Diagnostics, Inc. | Method and device for trichomonas detection |
| US8017103B2 (en) * | 2005-07-01 | 2011-09-13 | Board Of Regents, The University Of Texas System | Methods and compositions to diagnose trichomonas infection |
| US20070015224A1 (en) * | 2005-07-01 | 2007-01-18 | Board Of Regents, The University Of Texas System | Methods and compositions to diagnose Trichomonas infection |
| US7439028B2 (en) * | 2005-09-30 | 2008-10-21 | Board Of Regents, The University Of Texas System | Methods and compositions to correlate Trichomonas infection with prostate cancer |
| US7803567B2 (en) * | 2005-12-09 | 2010-09-28 | Board Of Regents, The University Of Texas System | Methods and compositions for detecting trichomonas in a sample contacted with fixative |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK493984A (da) * | 1983-10-24 | 1985-04-25 | Univ Texas | Hybrid celle linier, monokloniske antistoffer frembragt med disse samt diagnosemetode under anvendelse af antistofferne |
| US4707442A (en) * | 1983-10-24 | 1987-11-17 | Board Of Regents, The University Of Texas System | Hybrid cell line producing monoclonal antibody cytolytic to Trichomonas vaginalis |
| GB8426461D0 (en) * | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
-
1986
- 1986-09-05 IL IL79950A patent/IL79950A0/xx not_active IP Right Cessation
-
1987
- 1987-09-03 AU AU77790/87A patent/AU7779087A/en not_active Abandoned
- 1987-09-04 US US07/093,431 patent/US5004694A/en not_active Expired - Fee Related
- 1987-09-04 DE DE87112995T patent/DE3787239T2/de not_active Expired - Fee Related
- 1987-09-04 EP EP87112995A patent/EP0259807B1/fr not_active Expired - Lifetime
- 1987-09-04 ES ES87112995T patent/ES2059336T3/es not_active Expired - Lifetime
- 1987-09-04 ZA ZA876627A patent/ZA876627B/xx unknown
- 1987-09-05 JP JP62222893A patent/JPS63211298A/ja active Pending
- 1987-09-08 CA CA000546325A patent/CA1327168C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU7779087A (en) | 1988-03-10 |
| EP0259807A2 (fr) | 1988-03-16 |
| IL79950A0 (en) | 1986-12-31 |
| US5004694A (en) | 1991-04-02 |
| ES2059336T3 (es) | 1994-11-16 |
| DE3787239T2 (de) | 1993-12-16 |
| DE3787239D1 (de) | 1993-10-07 |
| EP0259807B1 (fr) | 1993-09-01 |
| EP0259807A3 (en) | 1989-05-03 |
| ZA876627B (en) | 1988-05-25 |
| JPS63211298A (ja) | 1988-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI111336B (fi) | Menetelmä Staphylococcus epidermidis tyyppi I:n polysakkaridiantigeenin sisältävän rokotteen ja antigeeninvastaisen hyperimmunoglobuliinin valmistamiseksi | |
| US5196337A (en) | Human monoclonal antibody, and its production and use | |
| EP0286099A2 (fr) | Anticorps monoclonaux réagissant avec une endotoxine nucléaire | |
| DE3642095A1 (de) | Monoclonale antikoerper, die kreuzreaktiv und kreuzprotektiv gegen p. aeruginosa-serotypen sind | |
| CA1327168C (fr) | Anticorps monoclonaux anti-trichomonas vaginalis | |
| EP0057107A2 (fr) | Procédé de préparation d'anticorps monoclonaux et cellules aptes à produire ces anticorps | |
| EP0093775A1 (fr) | Anticorps monoclonaux contre le brugia malayi | |
| EP0193576A1 (fr) | Anticorps monoclonaux et leur utilisation | |
| EP0233289B1 (fr) | Hybriodomes produisant anti-pseudomonas aeruginosa human monoclonal antibody | |
| EP0176365B1 (fr) | Anticorps monoclonal humain et sa préparation | |
| US4707442A (en) | Hybrid cell line producing monoclonal antibody cytolytic to Trichomonas vaginalis | |
| KR910002373B1 (ko) | 슈도모나스 에루기노사 편모에 대한 단일클론항체 | |
| EP0215131B1 (fr) | ANTIGENE E87Ag DU PSEUDOMONAS AERUGINOSE, ANTICORPS MONOCLONAL CONTRE CET ANTIGENE ET HYBRIDOME | |
| JP2565303B2 (ja) | 緑膿菌感染症の予防治療剤 | |
| EP0327648B1 (fr) | Anticorps monoclonal humain et medicament pour la prophylaxie et le traitement de maladies infectieuses comprenant ledit anticorps en tant qu'ingredient efficace | |
| JPS60156383A (ja) | 膣トリコモナス決定因子に対して向けられたモノクロ−ナル抗体を産生するハイブリツド細胞系統 | |
| EP0200745A1 (fr) | Anticorps monoclonaux et leur utilisation | |
| Moav et al. | Anti-Trichomonas vaginalis monoclonal antibodies inducing complement-dependent cytotoxicity. | |
| CA1294905C (fr) | Anticorps monoclonal pour le diagnostic de la maladie de lafora | |
| EP0326148A1 (fr) | Anticorps monoclonal humain spécifique à Pseudomonas aeruginosa et lignes de cellules hybrides | |
| EP0201519A1 (fr) | Anticorps monoclonaux et leur utilisation | |
| WO1987006469A1 (fr) | Anticorps monoclonaux et leur utilisation | |
| EP0189451A1 (fr) | Anticorps monoclonaux et leur utilisation | |
| AU708879B2 (en) | Means for detection of bacteria of the species Taylorella equigenitalis and their biological applications | |
| EP0243174A2 (fr) | Anticorps monoclonaux contre une exo-enzyme S de Pseudomonas aeruginosa, leur préparation et leur utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |